Regulatory NewsBREAK: CMS Announces List of Selected Drugs for IPAY 2028
- On January 27, 2026, the Centers for Medicare and Medicaid Services (CMS) announced the list of drugs selected for the third round of the Medicare Drug Price Negotiation Program.
- For the first time, the list includes drugs payable under Part B in addition to Part D.
- The selected drug list for the third cycle of negotiations:
- Anoro Ellipta
- Biktarvy
- Botox; Botox Cosmetic
- Cimzia
- Cosentyx
- Entyvio
- Erleada
- Kisqali
- Lenvima
- Orencia
- Rexulti
- Trulicity
- Verzenio
- Xeljanz; Xeljanz XR
- Xolair
- In addition, CMS announced the selection of one drug chosen for renegotiation:
- Tradjenta
- The negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective in 2028.
Related
On January 23, 2026, the U.S. Department of Health and Human Services’ Office for Civil Rights (OCR) issued three notices: Rescission of Guidance to Nation’s Retail Pharmacies: Obligations under Federal Civil Rights Laws to Ensure Nondiscriminatory Access to Health Care at Pharmacies (Pharmacy Notice), Rescission of Guidance on Nondiscrimination Protections under the Church Amendments (Nondiscrimination Notice), and Rescission of Office for Civil Rights Documents under Executive Order 14192 (Additional Documents Notice).
On January 15, 2026, the White House released its Great Healthcare Plan (the Plan) as a broad framework for congressional action on lowering drug prices, lowering insurance premiums, and increasing price transparency. The Plan outlines several policy ideas for Congress to consider.
On January 5, 2026, the Centers for Disease Control and Prevention (CDC) revised the childhood and adolescent immunization schedule.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
